New York State Bar Association (NYSBA) DC- Area members are cordially invited to our Wednesday, December 14th NYSBA-DC event!
Holiday Networking Event: Reciprocity Issues for New York-Admitted Lawyers
Come join other NYSBA-DC area members in an information-sharing event to discuss reciprocity issues for New York-admitted lawyers — lawyers moving from state to state and dealing with bar licensure in various states, and how it is done in New York.
Margaret Nyland Wood, Esq., Assistant Deputy Clerk, New York State Court of Appeals
Kellie Early, Esq., Chief Operating Officer, National Conference of Bar Examiners, Madison, WI
Hosted by: Brian Malkin, Senior Counsel, McGuire Woods LLP
Date: Wednesday, December 14, 2016
Check-in: 4:45 pm
Program Begins: 5 PM
Wine & Cheese Reception: 6-7 PM
Location: McGuire Woods LLP 2001 K Street NW, Suite 400, Washington, DC 20006
Cost: FREE for NYSBA members
To Register: Reciprocity Issues for NY Admitted Lawyers
Please note: You will need to log in to www.nysba.org in order to register. If you need help with your NYSBA login in, please call our Member Resource Center at 800-582-2452.
For more information: email@example.com
We hope to see you on December 14th!
McGuireWoods’ Food and Beverage Industry Team is proud to have written the nation’s leading treatise on Food Safety Law. Jim Neale and Angela Spivey co-authored the authoritative work, which should be on the bookshelf of anyone practicing in the regulatory compliance or litigation of food safety arenas. The treatise enjoys a foreword by Bill Marler, one of the nation’s leading plaintiff’s side food safety attorneys and is updated twice a year to ensure that it contains the most timely and relevant information. Release Number 11 is now available. It features a detailed discussion of the long-awaited final rules implementing the Food Safety Modernization Act, such as the Sanitary Transport Rule, the Food Defense Rule, and the Hazard Analysis and Risk-Based Preventive Control Rule. It also addresses the FDA’s new Generally Accepted as Safe (“GRAS”) and Nutritional Labeling Rules. In addition, this Release analyzes the latest case law on consumer class action lawsuits challenging food labeling; insurance and indemnity caselaw relating to food production and food contamination; and causation in foodborne illness cases. Release 11 also discusses the National Bioengineered Food Disclosure Standard, which will create, for the first time, a uniform federal law on GMO and bioengineering disclosure, displacing state laws such as Vermont Act 120. The treatise is available in print and electronic form and should be part of the library of any reader of FDA Life. You can order your copy at this LINK.
On November 10, 2016, McGuireWoods LLP and McGuireWoods Consulting (“McGuireWoods”) will be holding its 8th Annual Pharmaceutical and Medical Device Conference in Chicago. Kicking off the Conference will be Keynote Speaker, Susan Winckler, the Chief Risk Management Officer for Leavitt Partners as well as a lead contributor in the firm’s alliance management and regulatory consulting activities. Winckler, a pharmacist and attorney by training, is the former FDA Chief of the Staff and former President and Chief Executive Officer of the Food and Drug Law Institute, a nonprofit organization based in Washington, D.C., which provides a marketplace for discussing food and drug law issues through conferences, publications, and member interaction. Continue Reading
On November 3, 2016, the New York State Bar Association’s Sections, Food, Drug and Cosmetic Law and Antitrust Law, held a program in New York City: “REMS and Other Drug Distribution Restrictions: When Does a Brand Company Have a Duty to Deal with its Generic Rivals?” The program featured both federal and state antitrust lead attorneys working on these issues, as well as counsel for both reference and generic applicants, including:
Elinor R. Hoffmann, Office of the New York State Attorney General
Peter Safir, Covington & Burling LLP
Daniel W. Butrymowicz, Federal Trade Commission
Seth Silber, Wilson Sonsini Goodrich & Rosati
William Reiss, Robins Kaplan LLP
Janet B. Linn, Bleakley Platt & Schmidt, LLP Continue Reading
On November 3, 2016, the New York State Bar Association’s Sections, Food, Drug and Cosmetic Law and Antitrust Law, will put on a program in New York City: “REMS and Other Drug Distribution Restrictions: When Does a Brand Company Have a Duty to Deal with its Generic Rivals?” The program will be held from 6:00-9:00 pm with a reception (cocktails and hors d’oeuvres) to follow. The speakers below feature both federal and state antitrust lead attorneys working on these issues, as well as counsel for both reference and generic applicants, to provide for a lively and informative discussion and dialog. Continue Reading
Join us for an interactive conference addressing key legal and business matters focusing on innovation, investing, and regulatory issues in the pharmaceutical and medical device sectors.
- Executive Roundtable – Life Sciences Industry Update
- FDA Update – Recent Developments and New Initiatives Impacting Pharmaceutical and Medical Device Companies
- HCP Relationships and Enforcement Issues
- Brexit Update
- Financing Alternatives for Life Sciences Companies
- Business and Legal Issues for Early-Stage Companies
- Patent Prosecution and Litigation Issues for Life Sciences Companies
- Hot Button Antitrust Issues for Life Science Companies
- Business and Legal Issues in Clinical Research Arrangements
- Company Presentations
On October 21, 2016, at the end of the week of AdvaMed 2016, FDA’s Center for Devices and Radiological Health (CDRH) unveiled its new page, “Reporting Allegations of Regulatory Misconduct.” According to the new page: Continue Reading
On October 18, 2016, the Friends of Cancer Research and the Duke-Margolis Center for Health Policy will convene a half-day forum bringing together clinicians, originator and biosimilar drug sponsors, advocates, regulators, and payers to tackle remaining uncertainty surrounding the future of the U.S. biosimilars market. The Forum, “The Future of the U.S. Biosimilars Market: Development, Education, and Utilization” will be held in Washington, D.C. at the Washington Marriott – Georgetown, 1221 22nd Street, NW. Continue Reading
On October 13, 2016, FDAnews is hosting its first in-person briefing at McGuireWoods LLP’s DC Office with the topic: “Expanded Access: FDA’s New Regulatory Process How Compassionate Use Fits into Proposed Reforms“. The Briefing brings together key representatives from FDA, Industry, Patient Advocacy, Academia, and the Hill in a unique setting to comprehensively address FDA’s latest thinking on expanded access / compassionate use programs and how the 21st Century Cures Act and other bills being considered in Congress may affect those programs going forward. The Briefing features as its Keynote Speaker, Richard Klein, Director, Patient Liaison Program, Office of Health and Constituent Affairs, Office of the Commissioner, FDA, a nationally-recognized speaker on FDA’s expanded access programs. McGuireWoods LLP’s Brian Malkin and Kate Hardey will moderate the program, and McGuireWoods LLP is hosting the reception that follows the program. Continue Reading